会员体验
专利管家(专利管理)
工作空间(专利管理)
风险监控(情报监控)
数据分析(专利分析)
侵权分析(诉讼无效)
联系我们
交流群
官方交流:
QQ群: 891211   
微信请扫码    >>>
现在联系顾问~
热词
    • 23. 发明申请
    • CONJUGATED SURAMIN OR DERIVATIVES THEREOF WITH PEG, POLYASPARTATE OR POLYGLUTAMATE FOR CANCER TREATMENT
    • 用PEG,聚天冬氨酸或聚谷氨酸盐共轭的SURAMIN或其衍生物用于癌症治疗
    • WO9943311A2
    • 1999-09-02
    • PCT/US9904336
    • 1999-02-26
    • US HEALTHWEBB CRAIG PJEFFERS MICHAEL ECZERWINSKI GREGORZMICHEJDA CHRISTOPHER JVANDE WOUDE GEORGE F
    • WEBB CRAIG PJEFFERS MICHAEL ECZERWINSKI GREGORZMICHEJDA CHRISTOPHER JVANDE WOUDE GEORGE F
    • A61K47/48C09B69/10C12Q1/37A61K31/185
    • C12Q1/37A61K47/60A61K47/645C09B69/106G01N2333/9723
    • The present invention provides an assay that identifies compounds which inhibit cleavage of HGF/SF by serum proteases such as uPA, and methods in which such compounds are provided to reaction solutions, to cultured cells in vitro, or to a mammal in vivo, to inhibit cleavage of HGF/SF and to inhibit chemical and biological effects resulting from the activation of c-Met receptor by HGF/SF. The invention also provides methods for modifying suramin and suramin-related polysulfonated compounds that inhibit HGF/SF cleavage, by attaching PEG or polyanions such as polyglutamate or polyaspartate to the compounds to reduce cellular uptake of the compounds, thereby reducing their cytotoxicity. Also provided are a pharmaceutical composition containing at least one polysulfonated HGF/SF cleavage-inhibiting compound other than suramin, and a pharmaceutical composition containing at least one HGF/SF cleavage-inhibiting form of suramin or a suramin-related polysulfonated compound that is modified by conjugation to a chemical moiety that reduces uptake of the compound into cells. The present invention further includes methods wherein such pharmaceutical compositions are administered to a mammal with a tumor that is stimulated to grow by HGF/SF, to inhibit the growth or metastasis of the tumor in the mammal.
    • 本发明提供了鉴定通过血清蛋白酶如uPA来抑制HGF / SF裂解的化合物的测定法,以及将这些化合物提供给反应溶液,体外培养细胞或体内哺乳动物以提供抑制 切割HGF / SF并抑制由HGF / SF激活c-Met受体引起的化学和生物效应。 本发明还提供了通过将PEG或聚阴离子如聚谷氨酸盐或聚天冬氨酸连接到化合物以减少化合物的细胞摄取从而减少它们的细胞毒性来修饰抑制HGF / SF切割的苏拉明和苏拉明相关多磺化化合物的方法。 还提供了一种药物组合物,其含有至少一种除苏拉明以外的多磺化HGF / SF裂解抑制化合物,以及一种药物组合物,该药物组合物含有至少一种被修饰的苏拉明或苏拉明相关多磺化化合物的HGF / SF切割抑制形式 缀合至减少化合物向细胞摄取的化学部分。 本发明进一步包括这样的方法,其中将这种药物组合物给予患有被HGF / SF刺激生长的肿瘤的哺乳动物,以抑制哺乳动物中肿瘤的生长或转移。
    • 27. 发明申请
    • METHOD FOR ANALYZING A NUCLEIC ACID
    • 分析核酸的方法
    • WO2003035893A2
    • 2003-05-01
    • PCT/US2002/033788
    • 2002-10-22
    • CURAGEN CORPORATIONBOUFFARD, PascalHERRMANN, John, L.HUANG, ChunliJEFFERS, Michael, E.JU, JingfangRASTELLI, LucaSHIMKETS, Juliette, B.SIMONS, Jan, FredikTAILLON, Bruce, E.
    • BOUFFARD, PascalHERRMANN, John, L.HUANG, ChunliJEFFERS, Michael, E.JU, JingfangRASTELLI, LucaSHIMKETS, Juliette, B.SIMONS, Jan, FredikTAILLON, Bruce, E.
    • C12Q
    • C12Q1/6855G06F19/22
    • Disclosed is a method in which DNA sequences derived from microsome-associated mRNA sequences in a mixed sample or in an arrayed single sequence clone can be determined and classified without sequencing. The methods make use of information on the presence of carefully chosen target subsequences, typically of length from 4 to 8 base pairs, and preferably the length between target subsequences in a sample DNA sequence together with DNA sequence databases containing lists of sequences likely to be present in the sample to determine a sample sequence. The preferred method uses restriction endonucleases to recognize target subsequences and cut the sample sequence. Then carefully chosen recognition moieties are ligated to the cut fragments, the fragments amplified, and the experimental observation made. Polymerase chain reaction (PCR) is the preferred method of amplification. Another embodiment of the invention uses information on the presence or absence of carefully chosen target subsequences in a single sequence clone together with DNA sequence databases to determine the clone sequence. Computer implemented methods are provided to analyze the experimental results and to determine the sample sequences in question and to carefully choose target subsequences in order that experiments yield a maximum amount of information.
    • 公开了可以确定和分类来自混合样品或排列单序列克隆中的微粒体相关mRNA序列的DNA序列而不进行测序的方法。 这些方法利用关于精确选择的目标子序列的存在的信息,通常长度为4至8个碱基对,优选样品DNA序列中目标子序列之间的长度以及含有可能存在的序列的DNA序列数据库 在样品中确定样品序列。 优选的方法是使用限制性核酸内切酶识别目标子序列并切割样品序列。 然后仔细选择识别部分连接到切割片段,扩增片段,并进行实验观察。 聚合酶链反应(PCR)是优选的扩增方法。 本发明的另一个实施方案使用关于在单个序列克隆中与DNA序列数据库一起存在或不存在仔细选择的目标子序列的信息来确定克隆序列。 提供计算机实现的方法来分析实验结果并确定所讨论的样本序列,并仔细选择目标子序列,以便实验产生最大量的信息。